Healthy Subjects
Conditions
Keywords
HIV
Brief summary
The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.
Detailed description
The study includes two parts. Part 1 is to evaluate the impact of Emtricitabine on HS-10234. Part 2 is to evaluate the impact of HS-10234 on Emtricitabine.
Interventions
DRUGHS-10234
HS-10234
DRUGEmtricitabine
Emtricitabine
Sponsors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Voluntarily sign an informed consent before any activities related to this trial and understand the procedures and methods of this trial; 2. Aged between 18 and 55 years old (including cutoff value), both male and female; 3. Male body weight ≥50.0kg, female body weight ≥45.0kg, body mass index (BMI) is 19\ 26 kg/m2 (including both ends); 4. Those who signed the informed consent form and had no birth plan within 3 months after the last dose and agreed to take effective contraceptive measures.
Exclusion criteria
1. People who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other diseases that can interfere with the test results, Or have a stomach problem or have a history of stomach problems; 2. People who have drugs (penicillin or cephalosporin drugs), food, or have a history of allergy to test drugs or similar drugs; 3. If the subject have a history of surgery within the 4 weeks prior to the trial or plan to undergo surgery during the study period or have surgery that affected the absorption, distribution, metabolism, and excretion of drugs; 4. Those who took any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drug, or those who were within 5 half-lives of the drug at the time of screening; those who plan to take non-study drugs or health products during the trial; 5. Those who participated in any drug clinical trial and used any trial drug within 3 months before administration (subject to the informed consent); 6. Participate in blood donation within 3 months before administration and the amount of blood donation \>200 mL, or have received blood transfusion; 7. Unable or unwilling to follow the lifestyle guidelines required in the plan; 8. Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the trial; 9. Alcoholics or frequent drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) or before administration Alcohol screening positive; 10. People who have a history of drug abuse, drug dependence, or a positive drug screen before administration; 11. Screening/baseline visit to alanine aminotransferase and/or aspartate aminotransferase and/or alkaline phosphatase and/or total bilirubin exceeds 1.2 times the upper limit of normal; 12. Abnormal vital signs (systolic blood pressure \<90 mmHg or \>140 mmHg, diastolic blood pressure \<50 mmHg or \>90 mmHg; pulse \<50 bpm or \>100 bpm) or physical examination, electrocardiogram, laboratory examination, imaging examination, etc. Abnormality has clinical significance (subject to the judgment of the clinical research doctor); 13. The QT interval is prolonged during screening (calculated using Bazett's method, male\>450 msec, female\>460 msec); 14. Hepatitis B surface antigen, hepatitis C antibody, syphilis serotonin, HIV antibody test positive; 15. Women during pregnancy or lactation; 16. Subjects may not be able to complete the study for other reasons or the investigator believes that they should not be included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine | 0 - 24 hour on 7th day | Cmax |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of HS-10234's metabolite tenofovir-diphosphate in peripheral blood mononuclear cells. | 0 - 24 hour on 7th day | Concentration |
| Incidence of AEs, | 0 - 23 day | laboratory abnormalities (based on hematology, biochemistry, and urinalysis tests) |
Countries
China
Outcome results
None listed